Chicago Lymphoma Symposium 2022 Agenda

Target Audience

This activity has been designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma
  • Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma
  • Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data
  • Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL
  • Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma
Time (CDT)

Interprofessional Session

FRIDAY, APRIL 29, 2022
8:00 AM – 8:15 AM

Welcome and Introductions
Andrew Evens, DO, MSc, FACP

8:15 AM – 9:35 AM

Jacklyn Gideon, MSN, AGPCNP-BC – Moderator​
8:15 AM – 8:55 AM
Cellular therapy in lymphoma: where are we now? CAR T-cell therapy and bispecific antibodies
Peter Riedell, MD
8:55 AM – 9:35 AM

Venous thromboembolism in lymphoma: risk stratification, prophylaxis, and treatment

Kenneth Cohen, MD
9:35 AM – 10:05 AM
Break & Exhibits
10:05 AM – 11:55 AM

Leo Gordon, MD – Moderator

10:05 AM – 10:45 AM

COVID-19 in patients with lymphoma: impact on treatment approaches, vaccination responses, and prophylactic/therapeutic antiviral strategies

Natasha Pettit, PharmD, BCPS
10:45 AM – 11:45 AM

Toxicities with chronic therapies – case studies

Katherine Thorp, NP and Nicole Soriano, PharmD, BCOP
11:00AM – 11:45 AM

Q&A

11:55 AM – 12:00 PM

Session Wrap-Up and Closing

Andrew Evens, DO, MSc, FACP
Friday,  April 29
General Session
1:00 PM – 1:10 PM

Welcome and Introductions

Andrew Evens, DO, MSc, FACP

1:10 PM – 3:00 PM
Mini Symposium on Follicular Lymphoma (FL)

Andrew Evens, DO, MSc, FACP – Moderator

1:10 PM– 1:15 PM

Presession ARS
1:15 PM – 1:35 PM
Biology of FL

Robert Kridel, MD, MPH, PhD

1:35 PM – 1:55 PM

Targeted agents in FL – how and when to choose?

Tycel Phillips, MD

1:55 PM – 2:15 PM

Immunotherapy for FL

Sairah Ahmed, MD

2:15 PM – 2:35 PM

Management of the patient with FL patient in the COVID-19 era

Leo Gordon, MD

2:35 PM – 3:00 PM
Panel discussion with speakers, Q&A, and postsession ARS
3:00 PM – 3:30 PM
Break & Exhibits

3:30 PM – 4:55 PM

Mini Symposium on Mantle Cell Lymphoma (MCL)

Peter Riedell, MD – Moderator

3:30 PM – 3:50 PM

Case presentations – how would you treat?

Reem Karmali, MD

Newly diagnosed MCL and potential role of autologous stem-cell transplantation.
3:50 PM – 4:40 PM
Relapsed MCL – suboptimal response to a Bruton Tyrosine Kinase (BTK) inhibitor…do you continue treating with the BTK inhibitor or proceed to CAR T-cell therapy?
Debate – role of auto transplant

Timothy Fenske, MD | Patrick Stiff, MD

Patrick Stiff, MD

4:40 PM – 4:55 PM

Sequencing of therapies in R/R MCL

Kami Maddocks, MD

4:55 PM – 5:00 PM
General Session Wrap Up and Summary
IUCLS Chairs
5:15 PM – 6:15 PM 

Welcome Reception with Exhibitors

Time (CDT)
General Session
MORNING | SATURDAY, APRIL 30, 2022
7:00 AM – 8:00 AM
Breakfast

8:00 AM – 8:10 AM

Welcome and Introductions

Timothy Fenske, MD

8:10 AM – 10:00 AM
Mini Symposium on Hodgkin Lymphoma (HL)

Justin Kline, MD – Moderator

8:10 AM – 8:15 AM
Presession ARS

8:15 AM – 8:35 AM

Impact of the immune landscape on Hodgkin lymphoma prognosis and treatment

Christian Steidl, MD, PhD

8:35 AM – 8:55 AM

Treatment of 1st relapsed HL

Vaishalee Kenkre, MD

8:55 AM – 9:15 AM

Relapse after auto SCT, brentuximab vedotin, and checkpoint inhibitors – the next frontier

Anna Sureda, MD, PhD

9:15 AM – 9:35 AM
Postacute (years 1-10) outcomes in HL

Lindsay Morton, PhD

9:35 AM – 10:00 AM

Speaker panel discussion, audience Q&A, and postsession ARS
10:00 AM – 10:15 AM
Break & Exhibits
10:15 AM – 11:25 AM
Mini Symposium on Primary and Secondary Central Nervous System (CNS) Lymphoma

Timothy Fenske, MD – Moderator

10:15 AM – 10:20AM

Presession ARS

10:20 AM – 10:40 AM

Primary CNS lymphoma – focus on consolidation

Tracy Batchelor, MD, MPH

10:40 AM – 11:00 AM

CNS lymphoma prophylaxis

Craig Portell, MD

11:00 AM – 11:20 AM

Treatment of relapsed primary and secondary CNS lymphoma

Andres Ferreri, MD

11:20 AM – 11:25 AM
Audience Q&A
11:25 AM – 12:10 PM
Keynote Symposium: Frontline Treatment of Diffuse Large B cell Lymphoma (DLBCL)

Sonali Smith, MD, FASCO – Moderator

11:25 AM – 12:10 PM
Recent advances in the frontline treatment of DLBCL: Is there a new standard of care?

Laurie Sehn, MD, MPH

12:10 PM – 1:00 PM
Lunch and Exhibits
Time (CDT)
General Session
AFTERNOON | SATURDAY, APRIL 30, 2022
1:00 PM – 2:50 PM
Mini Symposium on Aggressive Lymphoma

Vaishalee Kenkre, MD – Moderator 

1:00 PM – 1:05 PM
Presession ARS
1:05 PM – 1:25 PM
High-Grade B-Cell Lymphomas, Not Otherwise Specific (HBGL NOS): how to differentiate and what to do?

David Scott, MBChB, PhD

1:25 PM – 1:45 PM
Prognostication and treatment of Burkitt lymphoma in the modern era?

Adam Olszewski, MD

1:45 PM – 2:05 PM
T-cell lymphomas: Impact of classification on treatment

Neha Mehta-Shah, MD

2:05 PM – 2:25 PM
How to sequence non–CAR T-cell therapy for relapsed DLBCL

Dan Landsburg, MD

2:25 PM – 2:50 PM
Speaker panel discussion, audience Q&A, and postsession ARS
2:50 PM – 4:20 PM
Mini Symposium on Next Generation Therapies

Nasheed Hossain, MD – Moderator

2:50 PM – 2:55 PM
Presession ARS
2:55 PM – 3:15 PM
What’s next for CLL?

Nicole Lamanna, MD

3:15 PM – 3:35 PM
CAR T-cell constructs:  current and future options

Tanya Siddiqi, MD

3:35 PM – 3:55 PM
Bispecific antibodies

Rajat Bannerji, MD, PhD

3:55 PM – 4:20 PM
Speaker panel discussion, audience Q&A, and postsession ARS

4:20 PM – 4:35 PM

Summary and Best of IUCLS

Sonali Smith, MD, FASCO | Andrew Evens, DO, MSc, FACP | Timothy Fenske, MD

4:35 PM
Closing Comments

Sonali Smith, MD, FASCO

4:40 PM
Adjourn